



IFW

Dkt. 41426-FA-PCT-US/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli et al.
Serial No.: 10/751,346 Group Art Unit: 1647
Filed: January 2, 2004 Examiner: Lei Yao
For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND
USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
October 11, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

COMMUNICATION CONFIRMING OCTOBER 4 AND 6, 2005 TELEPHONE
CONFERENCES WITH EXAMINER

This Communication is being submitted to confirm October 4 and 6, 2005 telephone conferences between Examiner Lei Yao of the U.S. Patent and Trademark Office and Brian Amos of the undersigned's office.

On October 4, 2005, Examiner Yao informed Mr. Amos by telephone that in the Restriction Requirement she had issued on March 8, 2005 in connection with the subject application, and to which applicants responded on September 8, 2005 electing Examiner's claim group I and species A, Examiner Yao had intended for applicants to choose a single species from each of the species in groups A, B and C enumerated by the Examiner. Examiner Yao further indicated that she required an election of the species in groups A, B and C by end of business on

Applicants: Ron S. Israeli, et al.
Serial No.: 10/751,346
Filed: January 2, 2004
Page 2

October 6, 2005 for the response filed by applicants on September 8, 2005 to be deemed properly responsive.

After reviewing the subject application, applicants deemed that Species C was no longer applicable as it referred to species in claims canceled by applicants is the response filed September 8, 2005. Accordingly, Mr. Amos contacted Examiner Yao by telephone later the same day (October 4, 2005) to point this out. In response, Examiner Yao stated that applicants were only required to elect a species from each of group A and B.

Mr. Amos contacted Examiner Yao by telephone on October 6, 2005 at 4 p.m. to confirm that applicants elect the species "antibody" from group A and the species "toxin" from group B, without traverse.

Accordingly, it is applicants understanding that examination will proceed on claim group I, i.e. claims 21-31 in light of the fact that applicants have canceled claims 1-20 and 32-58 without prejudice, and species "antibody" from group A and species "toxin" from group B.


Please contact the undersigned if there is any misunderstanding on our part with respect to this matter.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


Applicants: Ron S. Israeli, et al.
Serial No.: 10/751,346
Filed: January 2, 2004
Page 3

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
	10/11/05
John P. White Reg. No. 28,678	Date